Logo image of SXTP

60 DEGREES PHARMA INC (SXTP) Stock Fundamental Analysis

NASDAQ:SXTP - Nasdaq - US83006G4010 - Common Stock - Currency: USD

2.3404  +0.06 (+2.65%)

Fundamental Rating

2

Overall SXTP gets a fundamental rating of 2 out of 10. We evaluated SXTP against 198 industry peers in the Pharmaceuticals industry. SXTP may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, SXTP is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year SXTP has reported negative net income.
In the past year SXTP has reported a negative cash flow from operations.
SXTP had negative earnings in each of the past 5 years.
In the past 5 years SXTP always reported negative operating cash flow.
SXTP Yearly Net Income VS EBIT VS OCF VS FCFSXTP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -2M -4M -6M -8M

1.2 Ratios

SXTP has a Return On Assets of -146.38%. This is amonst the worse of the industry: SXTP underperforms 81.82% of its industry peers.
SXTP has a worse Return On Equity (-208.90%) than 69.70% of its industry peers.
Industry RankSector Rank
ROA -146.38%
ROE -208.9%
ROIC N/A
ROA(3y)-224.71%
ROA(5y)-219.13%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SXTP Yearly ROA, ROE, ROICSXTP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

1.3 Margins

SXTP's Gross Margin of 43.53% is fine compared to the rest of the industry. SXTP outperforms 60.61% of its industry peers.
In the last couple of years the Gross Margin of SXTP has declined.
The Profit Margin and Operating Margin are not available for SXTP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 43.53%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.49%
GM growth 5YN/A
SXTP Yearly Profit, Operating, Gross MarginsSXTP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

More info and screens

3

2. Health

2.1 Basic Checks

SXTP does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SXTP has more shares outstanding
Compared to 1 year ago, SXTP has a worse debt to assets ratio.
SXTP Yearly Shares OutstandingSXTP Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M
SXTP Yearly Total Debt VS Total AssetsSXTP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

Based on the Altman-Z score of -13.36, we must say that SXTP is in the distress zone and has some risk of bankruptcy.
SXTP has a Altman-Z score of -13.36. This is in the lower half of the industry: SXTP underperforms 76.77% of its industry peers.
SXTP has a Debt/Equity ratio of 0.04. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of SXTP (0.04) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Altman-Z -13.36
ROIC/WACCN/A
WACC9.74%
SXTP Yearly LT Debt VS Equity VS FCFSXTP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 10M -10M -20M

2.3 Liquidity

A Current Ratio of 3.25 indicates that SXTP has no problem at all paying its short term obligations.
SXTP has a Current ratio (3.25) which is in line with its industry peers.
SXTP has a Quick Ratio of 2.98. This indicates that SXTP is financially healthy and has no problem in meeting its short term obligations.
SXTP has a Quick ratio of 2.98. This is comparable to the rest of the industry: SXTP outperforms 57.58% of its industry peers.
Industry RankSector Rank
Current Ratio 3.25
Quick Ratio 2.98
SXTP Yearly Current Assets VS Current LiabilitesSXTP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for SXTP have decreased strongly by -801.61% in the last year.
The Revenue has grown by 168.55% in the past year. This is a very strong growth!
Measured over the past years, SXTP shows a very negative growth in Revenue. The Revenue has been decreasing by -52.49% on average per year.
EPS 1Y (TTM)-801.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-228.7%
Revenue 1Y (TTM)168.55%
Revenue growth 3Y-52.49%
Revenue growth 5YN/A
Sales Q2Q%440.86%

3.2 Future

SXTP is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.74% yearly.
The Revenue is expected to grow by 82.46% on average over the next years. This is a very strong growth
EPS Next Y90.39%
EPS Next 2Y38.46%
EPS Next 3Y25.74%
EPS Next 5YN/A
Revenue Next Year109.78%
Revenue Next 2Y94.74%
Revenue Next 3Y82.46%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
SXTP Yearly Revenue VS EstimatesSXTP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2M 4M 6M
SXTP Yearly EPS VS EstimatesSXTP Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 -10 -20 -30 -40 -50

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SXTP. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SXTP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SXTP Price Earnings VS Forward Price EarningsSXTP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SXTP Per share dataSXTP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20 -30

4.3 Compensation for Growth

A more expensive valuation may be justified as SXTP's earnings are expected to grow with 25.74% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.46%
EPS Next 3Y25.74%

More info and screens

0

5. Dividend

5.1 Amount

SXTP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

60 DEGREES PHARMA INC

NASDAQ:SXTP (5/5/2025, 3:38:15 PM)

2.3404

+0.06 (+2.65%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-27 2025-03-27/amc
Earnings (Next)N/A N/A
Inst Owners2.09%
Inst Owner Change-0.46%
Ins Owners3.15%
Ins Owner Change9.31%
Market Cap3.44M
Analysts80
Price Target5.92 (152.95%)
Short Float %30.26%
Short Ratio0.21
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-138.25%
Min EPS beat(2)-247.17%
Max EPS beat(2)-29.33%
EPS beat(4)1
Avg EPS beat(4)-51.32%
Min EPS beat(4)-247.17%
Max EPS beat(4)119.61%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-24.26%
Min Revenue beat(2)-45.31%
Max Revenue beat(2)-3.22%
Revenue beat(4)0
Avg Revenue beat(4)-25.41%
Min Revenue beat(4)-45.31%
Max Revenue beat(4)-3.22%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-65.88%
PT rev (3m)70.59%
EPS NQ rev (1m)57.31%
EPS NQ rev (3m)-96.27%
EPS NY rev (1m)56.42%
EPS NY rev (3m)-125%
Revenue NQ rev (1m)-28.5%
Revenue NQ rev (3m)-24.33%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-20.9%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.05
P/FCF N/A
P/OCF N/A
P/B 0.85
P/tB 0.89
EV/EBITDA N/A
EPS(TTM)-39.64
EYN/A
EPS(NY)-3.81
Fwd EYN/A
FCF(TTM)-3.97
FCFYN/A
OCF(TTM)-3.84
OCFYN/A
SpS0.46
BVpS2.75
TBVpS2.64
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -146.38%
ROE -208.9%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 43.53%
FCFM N/A
ROA(3y)-224.71%
ROA(5y)-219.13%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.49%
GM growth 5YN/A
F-Score4
Asset Turnover0.12
Health
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 360.76%
Cap/Sales 26.58%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.25
Quick Ratio 2.98
Altman-Z -13.36
F-Score4
WACC9.74%
ROIC/WACCN/A
Cap/Depr(3y)258.14%
Cap/Depr(5y)228.76%
Cap/Sales(3y)28.01%
Cap/Sales(5y)17.57%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-801.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-228.7%
EPS Next Y90.39%
EPS Next 2Y38.46%
EPS Next 3Y25.74%
EPS Next 5YN/A
Revenue 1Y (TTM)168.55%
Revenue growth 3Y-52.49%
Revenue growth 5YN/A
Sales Q2Q%440.86%
Revenue Next Year109.78%
Revenue Next 2Y94.74%
Revenue Next 3Y82.46%
Revenue Next 5YN/A
EBIT growth 1Y-88.47%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-25.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-24.33%
OCF growth 3YN/A
OCF growth 5YN/A